Patents by Inventor Claus Kremoser

Claus Kremoser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LXR modulators with bicyclic core moiety
    Patent number: 11970484
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: February 9, 2023
    Date of Patent: April 30, 2024
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY
    Publication number: 20230357214
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: February 9, 2023
    Publication date: November 9, 2023
    Inventors: Christian GEGE, Olaf KINZEL, Eva HAMBRUCH, Manfred BIRKEL, Claus KREMOSER, Ulrich DEUSCHLE
  • LXR modulators with bicyclic core moiety
    Patent number: 11618747
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: April 4, 2023
    Assignee: OrsoBio, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY
    Publication number: 20210147398
    Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: June 28, 2019
    Publication date: May 20, 2021
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
  • AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS
    Publication number: 20200131144
    Abstract: The present invention relates to derivatives of formula (I) which bind to the liver X receptor (LXR? and/or LXR?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: July 18, 2018
    Publication date: April 30, 2020
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Manfred Birkel, Eva Hambruch, Ulrich Deuschle, Claus Kremoser
  • LIVER X RECEPTORS (LXR) MODULATORS
    Publication number: 20200115357
    Abstract: The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXR?) and act preferably as inverse agonists of LXR.
    Type: Application
    Filed: April 10, 2018
    Publication date: April 16, 2020
    Applicant: Phenex-FXR GmbH
    Inventors: Christian Gege, Manfred Birkel, Eva Hambruch, Ulrich Deuschle, Claus Kremoser
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 10485795
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 26, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • Novel FXR (NR1H4) binding and activity modulating compounds
    Publication number: 20190142814
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 16, 2019
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 10220027
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 5, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • Novel FXR (NR1H4) binding and activity modulating compounds
    Publication number: 20180200243
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: October 13, 2017
    Publication date: July 19, 2018
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) modulating compounds
    Patent number: 9938278
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: April 10, 2018
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Christian Gege, Claus Kremoser, Olaf Kinzel, Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Aaron C. Schmitt, William J. Watkins, Jianjun Xu
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 9820979
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: November 21, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • NOVEL FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20170298068
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: December 16, 2015
    Publication date: October 19, 2017
    Inventors: CHRISTIAN GEGE, Claus Kremoser, Olaf Kinzel, Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Aaron C. Schmitt, William J. Watkins, Jianjun Xu
  • Hydroxy containing FXR (NR1H4) modulating compounds
    Patent number: 9751874
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 5, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Christian Gege, Olaf Kinzel, Claus Kremoser, Aaron C. Schmitt
  • NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS
    Publication number: 20170143684
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 25, 2017
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 9539244
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 10, 2017
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS
    Publication number: 20160176861
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Christian Gege, Olaf Kinzel, Claus Kremoser, Aaron C. Schmitt
  • NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS
    Publication number: 20150342930
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: August 12, 2015
    Publication date: December 3, 2015
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 9139539
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: September 22, 2015
    Assignee: Gilead Sciences, Inc.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 8952042
    Abstract: The present invention relates to compounds of formula (1): where R, A, Q and Z are defined herein, or an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof. These compounds bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: February 10, 2015
    Assignee: Phenex Pharmaceuticals AG
    Inventors: Claus Kremoser, Ulrich Abel, Christoph Steeneck, Olaf Kinzel